Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kymera Therapeutics Inc (Kymera) is a biopharmaceutical company that discovers and develops small molecule therapeutics for protein degradation. The company's pipeline includes IRAK4 for the treatment of atopic dermatitis, hidradenitis suppurativa, macrophage activation syndrome, general pustular psoriasis and rheumatoid arthritis, IRAKIMiD for the treatment of MYD88 tumor, STAT3 for PTCL, LGL-L, CTCL and Solid Tumors. Kymera's other pipeline includes MDM2 for Liquid and Solid Tumors. The company also utilizes Pegasus a drug discovery platform that allows the discovery of selective small molecule protein degraders against disease-causing proteins throughout the body. Kymera is headquartered in Watertown, Massachusetts, the US.
Headquarters
United States of America
Address
500 North Beacon Street, 4th Floor, Watertown, Massachusetts, 02472
Website
www.kymeratx.com
Telephone
1 857 2855314
No of Employees
186
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KYMR (NASD)
Revenue (2022)
$78.6M
67.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
5.1%
(2022 vs 2021)
Market Cap*
$2.2B
Net Profit Margin (2022)
XYZ
43.4%
(2022 vs 2021)
* As of and is in US$
Kymera Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | Pegasus |
| IRAK4 -Atopic Dermatitis, Hidradenitis Suppurativa, Macrophage Activation Syndrome, General Pustular Psoriasis and Rheumatoid Arthritis | |
| IRAKIMiD (IRAK4, Ikaros, Aiolos) - MYD88 Tumors | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In May, the company entered into a partnership with NEOsphere Biotechnologies to identify new molecular glue targets. |
| 2023 | Regulatory Approval | In June, the company announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to KT-253 for the treatment of Acute Myeloid Leukemia (AML). |
| 2023 | Others | In May, the company presented positive Phase 1 clinical data from its lead program, KT-474 (SAR444656). |
Competitor Comparison
| Key Parameters | Kymera Therapeutics Inc | Nurix Therapeutics Inc | Equillium Inc | Viela Bio Inc | Cornerstone Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Watertown | San Francisco | La Jolla | Gaithersburg | Cranbury |
| State/Province | Massachusetts | California | California | Maryland | New Jersey |
| No. of Employees | 186 | 284 | 44 | 170 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bruce Booth | Chairman | Executive Board | 2015 | 48 |
| Nello Mainolfi | President; Director; Chief Executive Officer | Executive Board | 2019 | 44 |
| Bruce Jacobs | Chief Financial Officer | Senior Management | 2019 | 53 |
| Jeremy Chadwick, Ph.D | Chief Operating Officer | Senior Management | 2023 | - |
| Ellen Chiniara | Chief Legal Officer; Secretary | Senior Management | 2023 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer